PDF Archive

Easily share your PDF documents with your contacts, on the Web and Social Networks.

Share a file Manage my documents Convert Recover PDF Search Help Contact



Aarkstore Lonsurf (Colorectal Cancer) 2023 .pdf



Original filename: Aarkstore - Lonsurf (Colorectal Cancer) 2023.pdf
Title: Slide 1
Author: vina

This PDF 1.5 document has been generated by Microsoft® Office PowerPoint® 2007, and has been sent on pdf-archive.com on 21/05/2015 at 09:58, from IP address 111.119.x.x. The current document download page has been viewed 483 times.
File size: 787 KB (9 pages).
Privacy: public file




Download original PDF file









Document preview


Healthcare Market Research
Reports

For More Information Visit : www.aarkstore.com

Summary
GlobalData has released its new PharmaPoint Drug Evaluation report, “Lonsurf
(Colorectal Cancer) - Forecast and Market Analysis to 2023”. Colorectal cancer
(CRC) is the second leading cause of mortality among cancer patients in the world and is
the third most diagnosed cancer globally, and thus represents a huge burden on
healthcare systems. This report focuses on the current treatment landscape, unmet
needs, current pipeline, and commercial opportunities in the colorectal cancer market,
with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-,
second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic.
In terms of targeted treatments, the metastatic CRC treatment landscape is mature,
including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and
Vectibix (panitumumab), treatments that have extended the survival of metastatic
patients compared to chemotherapy-only regimens. However, high unmet needs remain
for the extension of survival of metastatic patients, and particularly those with KRAS
mutation-positive disease, for whom the epidermal growth factor receptor (EGFR)
inhibitors Erbitux and Vectibix are not recommended.

For More Information Visit : www.aarkstore.com

Scope
- Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an overview on the competitive
landscape.
- Detailed information on Lonsurf including product description, safety and efficacy
profiles as well as a SWOT analysis.
- Sales forecast for Lonsurf for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan
and China.

For More Information Visit : www.aarkstore.com

Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a
robust return
- Stay ahead of the competition by understanding the changing competitive landscape
for Colorectal Cancer
- Effectively plan your M&A and partnership strategies by identifying drugs with the
most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of
Lonsurf performance
- Obtain sales forecast for Lonsurf from 2013-2023 in top eight countries (the US,
France, Germany, Italy, Spain, the UK, Japan and China)

For More Information Visit : www.aarkstore.com

Table of Content
1. INTRODUCTION
2. Disease Overview
3. Disease Management
4. Competitive Assessment
5. Lonsurf
6.Appendix

For More Information Visit : www.aarkstore.com

List Of Tables
Table 1: TNM and Staging Classification System for CRC 15
Table 2: Symptoms of Colorectal Cancer 16
Table 3: Treatment Guidelines for CRC 21
Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the
Global Markets, 2013 22
Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the
Global Markets, 2013 23
Table 6: Leading Treatments for CRC, 2014 32
Table 7: Product Profile - Lonsurf 35
Table 8: Lonsurf SWOT Analysis, 2014 37
Table 9: Global Sales Forecasts ($m) for Lonsurf (TAS-102), 2013-2023 38
Table 10: Average Body Weight and Surface Area Across the 8MM 49
Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 53

For More Information Visit : www.aarkstore.com

Related Reports











Global Telemedicine market report
Global Clinical trial outsourcing report
Latest Chinese Guidance for Development, Evaluation, License Approval
of Biosimilars
2015 Strategies in the Global Hematology and Flow Cytometry Markets
2015 Strategies in the European Hematology and Flow Cytometry
Markets
2015 Strategies in the French Hematology and Flow Cytometry Markets
2015 Strategies in the German Hematology and Flow Cytometry Markets
2015 Strategies in the Italian Hematology and Flow Cytometry Markets
2015 Strategies in the Japanese Hematology and Flow Cytometry Markets
2015 Strategies in the Spanish Hematology and Flow Cytometry Markets

For More Information Visit : www.aarkstore.com

Follow Us
https://www.facebook.com/aarkstoredotcom

https://twitter.com/aarkstore

https://plus.google.com/+Aarkstoredotcom/posts

https://www.linkedin.com/company/aarkstore-enterprise

For More Information Visit : www.aarkstore.com

Contact Us
Office Address
Office No. - 809, 8th Floor,
B-Wing, Mahaavir Icon,
Plot No.- 89 & 90, Sector-15,
CBD-Belapur, Navi Mumbai – 400614,
Maharashtra, India.

Mail us at contact@aarkstore.com
24/7 Online Support: +91 9987295242
General Inquiries : +91 - 22 2756 4953

For More Information Visit : www.aarkstore.com


Related documents


aarkstore lonsurf colorectal cancer 2023
310812900 final announcement roicam 4
kasi vittal poster final
aarkstore ivd in vitro diagnostic testing world markets
aarkstore molecular diagnostics in infectious disease
aarkstore h1 global lng liquefaction and regasification


Related keywords